Out-of-hospital cardiac arrest: handle with care-comment on the resuscitation outcomes consortium cardiac epidemiologic registry

The efficacy and safety of trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI) study was designed to assess the potential long-term benefits of antianginal therapy after PCI. • Approximately, 6000 patients who had had a successful PCI performed <30 days before inclusion, for stable angina or NSTE-ACS, regardless of the presence or absence of angina symptoms after the index PCI, were randomized to receive trimetazidine at the dose of 35 mg twice daily or placebo in addition to routine post-PCI treatment, and followed for up to 4 years. • The incidence of the primary endpoint (a composite of cardiac death, hospital admission for a cardiac event, recurrence, or persistence of angina requiring the addition, switch, or increase of the dose of one of the antianginal drugs, or recurrent or persistent angina requiring coronary angiography) was not significantly different between the trimetazidine group [700 (23.3%) patients] and the placebo group [714 (23.7%); hazard ratio 0.98 (95% confidence interval 0.88–1.09); P ¼ 0.73]. Similar results were obtained in the elective and urgent PCI subgroups. Serious adverse events occurred with similar frequencies in the two treatment groups.